About InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Ustekinumab making it ideal for research use. This Ustekinumab biosimilar reacts with human p40 also known as IL-12β. p40 is a 40 kDa subunit of IL-12 and IL-23. IL-12 is a heterodimeric cytokine composed of subunits IL-12α p35 and IL-12β p40. The p40 subunit of IL-12 also combines with p19, a protein that shows no biological activity by itself, to form IL-23. IL-12 is secreted by activated monocytes, macrophages, and dendritic cells while IL-23 is secreted by activated dendritic cells and epithelial cells. IL-12 plays roles in T lymphocyte differentiation, IFNγ production, and NK cell cytotoxicity. The C17.8 antibody has been shown to neutralize both IL-12 and IL-23 bioactivity. Ustekinumab is used for the treatment of Crohn’s disease, plaque psoriasis, and psoriatic arthritis. InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman IL-12 p40 Reported ApplicationsFunctional assays FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility. PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
